论文部分内容阅读
目的：报告４例非何杰金氏淋巴瘤（ＮＨＬ）在外周血干细胞移植（ＰＢＰＣＴ）支持下接受超大剂量化疗（ＨＤＣ）的初步经验并评价所用ＰＢＰＣ动员方案的动员效果，预处理方案的耐受性以及ＰＢＰＣ回输后造血重建情况。方法：４例高危ＮＨＬ经常规化疗获首次缓解后，采用ＣＴＸ３５００ｍｇ／ｍ２＋Ｇ－ＣＳＦ３．５－５μｇ／（ｋｇ·次）＋Ｄｅｘａｍｅｔｈａｓｏｎｅ１０ｍｇ作动员方案，经ＣＢＶ＋Ｅｐｉｒｕｂｉｃｉｎ（ＣＴＸ３６００ｍｇ／ｍ２，ＶＰ－１６１２００ｍｇ／ｍ２．ＢＣＮＵ３００ｍｇ／ｍ２和Ｅｐｉｒｕｂｉｃｉｎ１００ｍｇ／ｍ２）或ＴＢＩ８Ｇｙ＋ＶＰ－１６１２００ｍｇ／ｍ２治疗后回输ＰＢＰＣ。结果：每例患者分离２次，分别采集到ＭＮＣ１．７－４．３×１０８／ｋｇ，ＣＦＵ－ＧＭ１．５－２．８×１０４／ｋｇ和ＣＤ＋３４细胞３．１－８．８×１０６／ｋｇ。回输ＰＢＰＣ后，均获快速重建造血功能，ＡＮＣ＞０．５×１０９／Ｌ和Ｐｔ＞５．０×１０９／Ｌ的时间为８～１２天和８～１６天。非造血系统毒性包括心脏毒性反应，恶心呕吐，轻度肝功能异常和粘膜炎等。结论：ＰＢＰＣＴ支持下超大剂量化疗是治疗ＮＨＬ安全可行的临床手段，值得进一步研究探索。
OBJECTIVE: To report the preliminary experience of 4 cases of non-Hodgkin’s lymphoma (NHL) receiving super-dose chemotherapy (HDC) with the support of peripheral blood stem cell transplantation (PBPCT) and evaluate the mobilization effect of the PBPC mobilization protocol used. Hematopoietic reconstitution after receiving and reinfusion of PBPC. Methods: Four cases of high-risk NHL were treated with chemotherapy for the first time. CTX3500mg/m2+G-CSF3.5-5μg/(kg·time)+Dexamethasone10mg was used as the mobilization protocol. CBV+Epirubicin (CTX3600mg/m2, VP-161200mg/m2.BCNU300mg/ PBPC was reinfused after m2 and Epirubicin 100 mg/m2) or TBI8Gy+VP-16 1200 mg/m2 treatment. Results: Each patient was isolated twice and MNC 1.7-4.3×108/kg, CFU-GM 1.5-2.8×104/kg and CD+34 cells 3.1-8.8×106/kg were collected. Kg. After reinfusion of PBPC, rapid reconstitution of blood was achieved. The time for ANC>0.5×109/L and Pt>5.0×109/L was 8 to 12 days and 8 to 16 days. Non-hematopoietic system toxicities include cardiotoxicity, nausea and vomiting, mild liver dysfunction, and mucositis. Conclusion: The large-dose chemotherapy supported by PBPCT is a safe and feasible clinical method for the treatment of NHL, and it is worth further investigation.